皮罗尼病的医疗治疗:系统性审查和贝叶斯元分析网络
Hyun Young Lee1, Jong Hyun Pyun2, Sung Ryul Shim3
1Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
The world journal of men's health
|June 29, 2023
概括
网络元分析发现皮罗尼病没有显著的医疗治疗方法.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
- 医学研究 医学研究
背景情况:
- 皮罗尼氏病 (PD) 影响阴茎健康和勃起功能.
- 寻求PD有效的医疗疗法,以改善患者的治疗结果.
研究的目的:
- 用网络元分析 (NMA) 来比较佩罗尼病 (PD) 与安慰剂治疗的各种医疗疗疗法的疗效.
- 研究PD的口服药物,内伤疗法和机械治疗方法.
主要方法:
- 在主要数据库中对随机对照试验 (RCT) 进行系统搜索,直到2022年10月.
- 包括的研究评估了曲率程度,斑块大小和国际勃起功能指数 (IIEF) 评分.
- 使用了网络元分析 (贝叶斯式和频率主义方法).
主要成果:
- 贝叶斯分析显示,治疗和安慰剂之间没有曲率,斑块大小或IIEF的统计学上显著差异.
- 频率分析表明,几种单一疗法 (例如,CoQ10,高热,PTT,维生素E) 和组合疗法在改善曲率和斑块大小方面具有潜在的疗效.
- 在基于SUCRA值的贝叶斯分析中,高温器件排名最高.
结论:
- 目前,在贝叶斯的NMA中,没有任何PD的医疗治疗方法在安慰剂上表现出明显的疗效.
- 频率主义分析表明,特定的药物具有潜在的益处,需要进一步调查.
- 需要进行额外的研究来确定和验证对皮罗尼病更有效的治疗选择.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
197
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
197
01:27Peripheral Artery Disease III: Interprofessional Care
13
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
13
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
204
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
204
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
212
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221